An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.
An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer.
复制标题
头颈癌中辅助化疗的随机对照试验的概述。
DOI：
10.1038/bjc.1995.17
复制
发表时间：
1995-01
影响因子：
8.8
通讯作者：
Munro, A J
中科院分区：
文献类型：
--
作者：
Munro, A J
对54项头颈癌辅助化疗随机对照试验的已发表结果进行荟萃分析，结果表明化疗可使绝对生存率提高6.5%（95%置信区间3.1-9.9%）。有利于化疗的比值比为1.37（95%置信区间为1.24-1.5）。单药化疗与放疗同步给药可使生存率提高12.1%（95%置信区间5-19%）。新辅助化疗的获益较少：率差为3.7%（95%置信区间0.9-6.5%）。结果表明，研究最佳药物和同步放化疗的时间表可能仍然是重要的，在头颈部肿瘤的临床试验。
Meta-analysis of the published results from 54 randomised controlled trials of adjuvant chemotherapy in head and neck cancer suggests that chemotherapy might increase absolute survival by 6.5% (95% confidence interval 3.1-9.9%). The odds ratio in favour of chemotherapy is 1.37 (95% confidence interval 1.24-1.5). Single-agent chemotherapy given synchronously with radiotherapy increased survival by 12.1% (95% confidence interval 5-19%). The benefit from neoadjuvant chemotherapy was less: a rate difference of 3.7% (95% confidence interval 0.9-6.5%). The results suggest that the investigation of optimal agents and scheduling for synchronous radiotherapy and chemotherapy might still be important in clinical trials in head and neck cancer.